Trevor Romeo

I was just wondering if you could give maybe an update on your cross-selling initiatives there.

I would love if you could speak to kind of how you're thinking about investing in the organics business, what you're seeing from a regulatory perspective

your PFAS remediation business, love if you could maybe talk about what kind of revenue you're expecting for that business

reshoring as well as maybe infrastructure funding and things like that as a medium-term, long-term tailwind

was the softness in this quarter kind of about what you expected last quarter when you lowered the guidance

Should we think about buybacks continuing to be maybe a bigger driver with the stock at these levels

any update there in terms of size, regions, any bias to one of the -- either Recycling & Waste or ES

any thoughts on, I guess, Q3 versus Q4 and the consolidated margins would be great

how much further opportunity you see there to increase efficiency and take some labor benefits

noticed that the MSW and the volumes were down, I think, 4% in the quarter. Just wondering if there was anything, you know, specific

where does that place you relative to kind of your historical averages? And then two, any sort of new initiatives

Just in terms of the revenue performance, just wondering if you could, I guess, talk about the pricing environment for hazardous waste

in terms of AI, there's a lot of hype out there. So would love your views on whether there are any new tools you're looking at

where are you kind of seeing pricing stick a little better than you thought? And what are the drivers of that?

I was hoping maybe you could level set how much cost synergy capture you realized in 2025 and then how much is baked in for incremental in 2026

I appreciate the, I guess, the 60% of volumes contracted for 2026. That's encouraging. For the 40% of the uncontracted volumes

If you could maybe just touch a little more on the deferral of the pricing increases. Just maybe like what kind of customers are pushing back and why

how are you thinking about both pieces of that spread into -- beyond this year

how much voluntary workforce turnover. Have you seen a Healthcare Solutions since the acquisition

I don't know if you had temporary volume benefits that boosted that, but it doesn't sound like you've done much on the medical waste side yet

Just wondering if you could share any anecdotes you've had from conversations with customers about sort of the combined value proposition

I guess, is the full $500 million included in your guidance now

if you could maybe talk about the Q4 like-for-like performance from a revenue and margin perspective for Stericycle

how are you thinking about the more cyclical portions of that volume and how likely they could be to rebound